Singapore markets close in 4 hours 20 minutes
Straits Times Index
3,283.24 -9.89 (-0.30%) Nikkei
37,680.91 -779.17 (-2.03%) Hang Seng
17,295.93 +94.66 (+0.55%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,324.38 -2,388.15 (-3.58%) CMC Crypto 200
1,385.53 -38.57 (-2.71%)
Gilead Sciences Inc (GIS.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
At close: 08:08AM CEST
| Previous close | 62.70 |
| Open | 62.49 |
| Bid | 62.67 x 110000 |
| Ask | 62.73 x 109000 |
| Day's range | 62.49 - 62.49 |
| 52-week range | 61.79 - 80.12 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWhat's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksGilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
© 2024 Yahoo. All rights reserved.